Every 8-K that Edgewell Personal Care Company (EPC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EPC filings page.
Edgewell Personal Care Company reported third-quarter fiscal 2026 net sales of $570.1 million, up 1.7% year over year, with organic net sales up 1.1%. North America organic sales rose 3.0% on stronger Sun, Skin Care and Grooming volumes, while international organic sales declined 1.4% due to Middle East disruptions and Wet Shave manufacturing consolidation impacts.
Gross profit was $242.5 million and gross margin was 42.5%, down 210 basis points; adjusted gross margin was 44.5%. GAAP diluted EPS from continuing operations was $0.26, down from $0.46, while adjusted EPS held at $0.72. Adjusted EBITDA was $78.9 million versus $81.2 million a year earlier. Edgewell ended the quarter with $397.1 million in cash, net debt of $882.1 million and an adjusted net debt leverage ratio of 3.7x. For fiscal 2026, the company now expects reported net sales to grow 1.3%–1.8%, GAAP EPS to be flat to $0.20, adjusted EPS of $1.80–$2.00 and adjusted EBITDA of $250–$260 million, while continuing to incur about $92 million of restructuring and related charges and paying a quarterly dividend of $0.15 per share.
Edgewell Personal Care Company announced a leadership change in its supply chain organization. The company determined that Paul R. Hibbert will no longer serve as Chief Supply Chain Officer, effective June 1, 2026, and he will be eligible for payments and benefits under Edgewell’s Executive Severance Plan.
Edgewell also disclosed that Anthony Freve will join the company as Chief Supply Chain Officer, with his appointment effective on the same date, June 1, 2026. The company publicly announced this leadership transition on May 26, 2026.
Edgewell Personal Care reported second-quarter fiscal 2026 net sales of $519.5 million, up 0.6%, while organic net sales fell 2.4%. GAAP diluted EPS from continuing operations dropped to $0.09 from $0.43, and adjusted EPS declined to $0.60 from $0.69.
Adjusted EBITDA from continuing operations was $73.8 million versus $84.7 million a year earlier, as gross margin and segment profits contracted despite productivity savings. The company reaffirmed its full-year outlook for organic net sales, adjusted EPS of $1.70–$2.10 and adjusted EBITDA of $245–$265 million, but lowered GAAP EPS guidance to flat–$0.40 due to higher restructuring and legal costs. Edgewell ended the quarter with $299.7 million in cash, a $418.8 million undrawn revolver and declared a $0.15 quarterly dividend.
Edgewell Personal Care Company reported first quarter fiscal 2026 results from continuing operations with net sales of $422.8 million, up 1.9% year over year, while GAAP diluted EPS was a loss of $(0.63) and adjusted EPS was $(0.16). Adjusted EBITDA from continuing operations was $25.0 million, down from $30.9 million a year earlier, as gross margin and operating margin compressed despite currency tailwinds and productivity savings.
The company completed the divestiture of its Feminine Care business for $340 million, now reported as discontinued operations, and ended the quarter with $223.3 million in cash and an adjusted net debt leverage ratio of 3.8x. Full‑year 2026 guidance for continuing operations keeps the prior outlook ranges, with reported net sales expected to grow about 0.5%–3.5%, GAAP EPS of $0.55–$0.95, adjusted EPS of $1.70–$2.10, and adjusted EBITDA of $245–$265 million, while restructuring charges are projected at approximately $65 million. Shareholders approved the 3rd Amended and Restated 2018 Stock Incentive Plan, adding 2,100,000 authorized shares for equity awards, and the board declared a quarterly dividend of $0.15 per share.
Edgewell Personal Care Company has completed the sale of its Feminine Care segment, including the Playtex, Stayfree, Carefree and o.b. brands, to Essity for $340 million in cash, subject to customary post‑closing adjustments. Edgewell plans to use the net proceeds, after taxes and transaction costs, primarily to strengthen its balance sheet by repaying its U.S. revolving credit facility and to continue investing in its core shave, sun and skin care, and grooming businesses.
At closing, Edgewell repaid $140 million outstanding on its revolving credit facility in the pro forma balance sheet, reducing long‑term debt. The company entered into a Transition Services Agreement to provide support services for at least one year, with options for Essity to extend certain services by three to six months. The Feminine Care business is treated as a discontinued operation, and Edgewell has provided unaudited pro forma financial information. On this basis, for the year ended September 30, 2025, net sales from continuing operations were $1,962.0 million and net earnings from continuing operations were $72.0 million, or $1.51 per diluted share, compared with historical continuing net earnings of $25.4 million, or $0.53 per diluted share.
Edgewell Personal Care Company furnished an update on its business, announcing financial and operating results for its fourth quarter and fiscal year ended September 30, 2025. The results were disclosed via a press release attached as Exhibit 99.1.
The company noted the information was provided under Item 2.02 and is being furnished, not deemed filed under Section 18 of the Exchange Act, and will not be incorporated by reference into other filings except as expressly stated. The press release was issued on November 13, 2025.
Edgewell Personal Care Company (EPC) entered into an Asset Purchase Agreement to sell its Feminine Care segment to Essity for $340 million in cash, subject to customary adjustments for inventory, indebtedness and other items.
Closing is subject to customary conditions, including required approvals under the HSR Act, no legal restraints, accuracy of representations and warranties, and compliance with covenants. Buyer-specific conditions include no material adverse effect on the business, no ongoing substantial destruction of manufacturing facilities, and certain third‑party consents.
The agreement includes customary termination rights if the deal is not completed by May 12, 2026, with automatic extensions to August 12, 2026 and November 12, 2026 if specified regulatory approvals remain outstanding. The Company may receive a $15 million termination fee from the Buyer under certain circumstances tied to regulatory efforts. The parties expect to enter a transition services agreement at closing.
Edgewell Personal Care Company announced that Daniel J. Sullivan, its Chief Operating Officer, informed the company on August 29, 2025 that he will resign from all roles effective October 1, 2025 to pursue another opportunity. The company furnished a press release on September 5, 2025 and attached it as Exhibit 99.1 to the Current Report. The filing states the resignation notice and press release are furnished under Regulation FD and clarifies that the disclosure is not being "filed" for Section 18 liability or incorporated by reference into other filings unless explicitly referenced. No financial statements, transaction details, or reasons beyond "to pursue another opportunity" are provided.
Edgewell Personal Care Company (EPC) filed a Form 8-K to disclose that, on 5 Aug 2025, it issued a press release announcing fiscal Q3 2025 operating and financial results. The release is furnished as Exhibit 99.1; no quantitative figures are included in the filing itself. The information is furnished under Item 2.02 and, per SEC rules, is not deemed "filed" for liability purposes nor incorporated into other securities filings unless specifically referenced.